A Dose Block-randomized, Double Blinded, Placebo Controlled, Dose-escalation Clinical Trial to Find the Maximal Tolerable Dose and to Evaluate the Safety, Tolerability and Pharmacokinetics After Single and Multiple Oral Doses of A4368 in Healthy Subjects
Latest Information Update: 20 Jan 2023
At a glance
- Drugs A 4368 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Autophagy Sciences
- 16 Jan 2023 Status changed from not yet recruiting to completed.
- 28 Jun 2021 New trial record